At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Apr 16, 2026 at 16:31 ET
Four insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemon, conducted open-market share sales totaling $1.13 million over a 7-day period, following derivative exercises. The net direction is selling, with the largest sale by director Christopher Patusky.
- CEO Martine Rothblatt sold $143K, CFO James Edgemon sold $298K, EVP Paul Mahon sold $115K, and Director Christopher Patusky sold $579K in open-market transactions.
- All insiders also exercised stock options or derivatives, including non-cash transactions at $0 strike price, which are routine and non-material.
- Total open-market sales: $1.13M, representing approximately 0.004% of the company's $25.8B market cap, well below the 0.1% threshold for materiality.
- Sales occurred at prices between $573.91 and $578.88 per share, consistent with recent trading levels.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access